Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Epidermolysis Bullosa Dystrophica 1Cytopenia 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory 1Adenocarcinoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 7Busulfan 5ruxolitinib 4Methotrexate 4Cyclosporine 4fludarabine phosphate 3Whole-Body Irradiation 2Mycophenolic Acid 2Flow Cytometry 2Cytogenetic Analysis 2Cytarabine 2Cyclophosphamide 2Antilymphocyte Serum 2venetoclax 1sonidegib 1pomalidomide 1pevonedistat 1pelcitoclax 1lestaurtinib 1givinostat hydrochloride 1givinostat 1ethanolamine oleate 1aldesleukin 1Vitamin E 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Topotecan 1Tacrolimus 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Polycythemia Vera × ON 01910 × Clear all
NCT01167166 2017-06-26

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Traws Pharma, Inc.

Phase 1/2 Completed
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡